OBJECTIVE To analyze the use of epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI)in the treatment of non-small cell lung cancer(NSCLC)in the past three years,and to provide a refer-ence for clinical safety and rational drug use.METHODS The sales amount,frequency of medication(DDDs),de-fined daily cost(DDC)and ranking ratio of hospital EGFR-TKI were retrospectively analyzed by using the limited daily dose(DDD)method.RESULTS In the past three years,the total sales and DDDs of EGFR-TKI in our hospi-tal have increased steadily,the sales,DDDs and proportion of the first generation of EGFR-TKI have decreased year by year,and the indicators of the third generation of EGFR-TKI represented by osimertinib have increased significant-ly,and the ranking ratio is well synchronized.CONCLUSION The use of EGFR-TKI in our hospital in the past three years is reasonable,and its medication trend is basically consistent with the situation reported in the literature,but it is still necessary to strengthen the approval system for medical insurance indications to ensure the safety,econo-my and effectiveness of clinical drugs.
关键词
非小细胞肺癌/EGFR-TKI/用药频度/合理用药
Key words
Non-small cell lung cancer/EGFR-TKI/Frequency of medication/Rational use of medicine
维普
万方数据